Gene · 2829
NIH grants1,173
NIH grants whose papers are about the gene, through NIH's grant-paper links.
41 to 60 of 1,173
Download this page as JSON| Grant | Title | XCR1 papers | Newest fiscal year |
|---|---|---|---|
| P30ES017885 | Michigan Center on Lifestage Environmental Exposures and Disease (M-LEEaD) | 2 | 2025 |
| R01AI121209 | Cooperation between lymphatic stroma and hematopoietic cells shapes protective immunity | 2 | 2025 |
| R01AI162643 | Molecular Basis of cDC1 Development | 2 | 2025 |
| R01AI163223 | A mechanism to minimize auto-reactivity in the tissue-resident memory T cell pool | 2 | 2025 |
| R01AI168423 | Evolution and design of metamorphic fold-switching proteins | 2 | 2025 |
| R01CA187975 | Regulation of stem-like CD8+ T cells and their role in immunotherapy | 2 | 2025 |
| R01CA197363 | The Tumor Microenvironment Niche of Type I conventional Dendritic Cells | 2 | 2025 |
| R01CA218668 | Computational and experimental methods for scalable identification of oncogenic non-coding regions | 2 | 2025 |
| R01CA248919 | Understanding the Mechanisms of DC Licensing in CD8 T Cell Priming | 2 | 2025 |
| R01DE026728 | Restoring the Immunogenicity of Head and Neck Cancer | 2 | 2025 |
| R01LM012806 | Predicting Phenotype by Deep Learning Heterogeneous Multi-Omics Data | 2 | 2025 |
| R24AI108564 | Research Resources: Epigenomic and Transcriptomic Profile of Human Immune Cells | 2 | 2025 |
| R35HL145241 | Vascular macrophages and T cells in atherosclerosis | 2 | 2025 |
| R37CA246239 | Potentiating Checkpoint Blockade by Cross-Priming Tumor-Reactive T cells with In Situ Vaccination | 2 | 2025 |
| T15LM011271 | San Diego Biomedical Informatics Education & Research (SABER) | 2 | 2025 |
| T32AI007290 | Molecular and Cellular Immunobiology | 2 | 2025 |
| T32AI007313 | Immunology Training Program | 2 | 2025 |
| T32AI007413 | Research Training in Experimental Immunology | 2 | 2025 |
| T32AI007496 | Interdisciplinary Training Program in Immunology | 2 | 2025 |
| T32CA009109 | Cancer Research Training Program: From Molecular Mechanisms to Therapeutic Strategies | 2 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2829/grants?page=3